Cell Therapeutics, Inc.

Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. It is developing paclitaxel poliglumex, which the Company has previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer. Cell Therapeutics, Inc. is also developing paclitaxel poliglumex as potential maintenance therapy for women with advanced stage ovarian cancer who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. The Company is developing pixantrone, an anthracycline derivative, for the treatment of non-Hodgkin’s lymphoma (NHL). An interim analysis of its ongoing phase III study of pixantrone, known as the EXTEND or PIX301 study, was performed by the independent Data Monitoring Committee during the year ended December 31, 2006. More from Reuters »